Total Payments
$11,616
2024 Payments
$3,105
Companies
83
Transactions
748
Medicare Patients
6,620
Medicare Billing
$3.2M
Payment Breakdown by Category
Food & Beverage$11,519 (99.2%)
Education$96.56 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,519 | 740 | 99.2% |
| Education | $96.56 | 8 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,104 | 79 | $0 (2024) |
| PFIZER INC. | $1,017 | 108 | $0 (2024) |
| Merck Sharp & Dohme LLC | $650.71 | 33 | $0 (2024) |
| Janssen Biotech, Inc. | $559.18 | 38 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $559.12 | 32 | $0 (2023) |
| Daiichi Sankyo Inc. | $515.89 | 30 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $466.83 | 24 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $385.12 | 38 | $0 (2024) |
| Celgene Corporation | $374.05 | 24 | $0 (2024) |
| GENZYME CORPORATION | $370.78 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,105 | 168 | ABBVIE INC. ($268.72) |
| 2023 | $2,699 | 144 | Merck Sharp & Dohme LLC ($263.51) |
| 2022 | $1,440 | 88 | Novartis Pharmaceuticals Corporation ($150.53) |
| 2021 | $477.99 | 28 | Novartis Pharmaceuticals Corporation ($105.15) |
| 2020 | $347.37 | 22 | Eisai Inc. ($63.56) |
| 2019 | $1,379 | 104 | Novartis Pharmaceuticals Corporation ($236.15) |
| 2018 | $1,320 | 119 | E.R. Squibb & Sons, L.L.C. ($208.56) |
| 2017 | $847.10 | 75 | PFIZER INC. ($141.78) |
All Payment Transactions
748 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: HORMONE THERAPY | ||||||
| 12/20/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.68 | General |
| 12/17/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $3.14 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Rare Disease | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $12.24 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: Iron Deficiency Anemia | ||||||
| 12/05/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.79 | General |
| 12/02/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Amneal Pharmaceuticals LLC | AVASTIN (Drug) | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $5.67 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), REBLOZYL, WELIREG | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: Immunology | ||||||
| 11/13/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: CELLT | ||||||
| 11/11/2024 | Cumberland Pharmaceuticals, Inc. | SANCUSO (Drug) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: Oncology | ||||||
| 11/06/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $32.36 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 38 | 1,537 | 62,518 | $2.3M | $952,296 |
| 2022 | 43 | 1,709 | 45,810 | $1.8M | $673,198 |
| 2021 | 42 | 1,744 | 61,620 | $2.5M | $1.0M |
| 2020 | 39 | 1,630 | 49,058 | $1.4M | $572,278 |
Total Patients
6,620
Total Services
219,006
Medicare Billing
$3.2M
Procedure Codes
162
All Medicare Procedures & Services
162 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 19 | 12,200 | $1.2M | $529,001 | 43.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 35 | 5,040 | $187,286 | $93,980 | 50.2% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 12 | 2,390 | $206,209 | $85,035 | 41.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 181 | 547 | $113,306 | $48,897 | 43.2% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 47 | 47 | $103,225 | $35,360 | 34.3% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 14 | 10,305 | $77,803 | $24,182 | 31.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 88 | 248 | $99,944 | $23,140 | 23.2% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 37 | 37 | $29,600 | $22,677 | 76.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 240 | 351 | $49,175 | $20,176 | 41.0% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 14 | 66 | $30,151 | $8,896 | 29.5% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 11 | 9,000 | $19,080 | $7,887 | 41.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 50 | 124 | $13,640 | $7,349 | 53.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 45 | 54 | $15,198 | $6,886 | 45.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 59 | 115 | $20,815 | $4,969 | 23.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $9,592 | $3,392 | 35.4% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 13 | 14 | $6,277 | $2,746 | 43.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $6,835 | $2,586 | 37.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 54 | 121 | $12,100 | $2,531 | 20.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 74 | 214 | $13,696 | $2,418 | 17.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 22 | 47 | $9,306 | $2,217 | 23.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 24 | $3,744 | $2,067 | 55.2% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 13 | 13 | $6,292 | $1,938 | 30.8% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 18 | 42 | $6,972 | $1,705 | 24.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 78 | 155 | $6,975 | $1,590 | 22.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $3,552 | $1,445 | 40.7% |
About Dr. Mark Romer, MD
Dr. Mark Romer, MD is a Medical Oncology healthcare provider based in Dayton, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023058427.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Romer, MD has received a total of $11,616 in payments from pharmaceutical and medical device companies, with $3,105 received in 2024. These payments were reported across 748 transactions from 83 companies. The most common payment nature is "Food and Beverage" ($11,519).
As a Medicare-enrolled provider, Romer has provided services to 6,620 Medicare beneficiaries, totaling 219,006 services with total Medicare billing of $3.2M. Data is available for 4 years (2020–2023), covering 162 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Dayton, OH
- Active Since 06/07/2006
- Last Updated 01/07/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1023058427
Products in Payments
- KEYTRUDA (Biological) $585.20
- IMBRUVICA (Drug) $487.06
- INJECTAFER (Drug) $330.34
- IBRANCE (Drug) $310.31
- Imbruvica (Drug) $308.18
- Lenvima (Drug) $308.02
- OPDIVO (Biological) $273.59
- VERZENIO (Drug) $223.96
- KISQALI (Drug) $206.59
- LIBTAYO (Biological) $196.81
- DARZALEX (Biological) $196.38
- GILOTRIF (Drug) $194.26
- Pomalyst (Drug) $191.38
- PROMACTA (Drug) $185.65
- Enhertu (Drug) $185.55
- XTANDI (Drug) $182.86
- BOSULIF (Drug) $148.42
- REBLOZYL (Biological) $143.09
- JEVTANA (Drug) $138.90
- Stivarga (Drug) $121.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.